Rev 10/29/15

CFAR Non-Competing Renewal (Progress Report)

Guidance: AppendixInstructions and Examples

1

USING THIS GUIDANCEFor the purposes of this Appendix Guidance, examples of completed tables are provided as they might have been compiled by a hypothetical “Urban University CFAR” for submission to NIH for their current reporting period, which covers Urban CFAR’s Project Year YR10 (8/1/14 – 7/31/15).

The complete list of YR10 Urban CFAR users who appear in this guidance is provided below. For each individual listed this includes: PI/PD name, where s/he is from, what CFAR User Categories s/he falls into, what roles s/he held within the CFAR, and the CFAR Cores and SWGs that provided support of some sort for him or her during the current reporting period.

All Urban CFAR Users in YR10

Name Location Categories Roles* CORES SWG

B C D F H J 1 21. Baba, Ali Urban U 2,5,6 CU X X2. Badenov, Boris Urban U 2 CU X X X X3. Banzai, Buckeroo Urban U 1 BDC,CU X X X X X4. Beckett, Sam Urban U 1 CU X X X X5. Boop, Betty Suburban CFAR 3, CU X X6. Bullfrog, Jeremiah W.A. Urban U 1 CU X7. Calvin, Susan Urban U 1 CD,CU,SD X X X X8. Coyote, Wile E. Suburban CFAR 4,5 CU X X X X X9. Croft, Lara Urban U 1,5 CU X X

10. Durga, Devi YRGC, Chennai 4,5,6 CU X X X11. Doolittle, John Urban U 3,5 CU X X X X12. Explorer, Dora T. Urban U 3,5 CU X X X X13. Falken, Stephen Urban U 3 CU X X X X14. Hackwrench, Gadget Urban U 4,5, 6 CU X X X15. Jones, Indiana Urban U 1 BDC,CU X X X16. Mephisto, Alphonse Urban U 2,5 CU,SM X X X X X17. Moreau, N.F.N. Urban U 2,5 CU,SM X X X X18. Neutron, Jimmy Rural CFAR 1 BDC,CU X X19. Omega, Zenith Urban U 1 BDC,CU X X X X X X20. Scully, Dana Area 51 D-CFAR 3 SM X21. Shango, Bumba KwaZulu-Natal 4,5,6 CU X X X22. Stein, Francis N. (Frank) Urban U 2 CU X X23. Who, Doctor Urban U 2,5 CU X X

*CD=Core Director, CU=Core User, SD=SWG Director, SM=SWG Member, BDC=Big Dogs Council

Rev 10/29/15 2

APPENDICES TABLE OF CONTENTS

The purpose of the Appendices Table of Contents is to help readers navigate to specific sections within the Appendices. When constructing your Table of Contents, follow the format provided below.

Appendix: A

A.1: [XXXX] FRB projects supported by the CFAR................................................................................2A.2: Other YR[#] NIH-funded projects supported by the CFAR................................................................

BB.1: External Advisory Board Report........................................................................................................B.2: Internal Advisory Board Report ........................................................................................................

CC.1: All Core B activities............................................................................................................................C.2: New Awards: Abstracts, progress reports..........................................................................................C.3: Active Projects: Progress reports .....................................................................................................C.4: Newly Completed Projects: Summary reports...................................................................................

DD.1: Core [X] ([Name]) Utilization Table and Other Significant Activities..................................................D.2: Core [X] ([Name]) Utilization Table and Other Significant Activities..................................................

Note: Each Science Core should appear in its own appendix subsection.

Rev 10/29/15 3

APPENDIX A: Support for NIH-funded ProjectsA.1

PURPOSE: To document the support that CFAR Cores provided to projects appearing on the FRB. Label the table with the NIH fiscal year whose FRB information is being reported. (See example below) Include one row on the table for each row appearing on the “ALLOW” tab of the most recent FRB report Excel sheet

o include those projects for which no Core assistance was provided Do NOT submit the actual FRB Excel spreadsheet with your report For each separate project list the Core(s) that provided a specific type of support for the project:

consultation (C), equipment or space (E/S), materials (M), services (S), training (T) or other (O) – for that project. Edit the standard “Roles” legend to include roles that are specific to your CFAR

[Example from Urban CFAR’s appendix A

2013 FRB “Allow” Tab Projects Supported by the CFARPI Roles* Categories Grant Title Grant # CORES THAT PROVIDED SUPPORT

C E/S M S T OBanzai, Buckeroo

CU, BDC 1 Giraffe models of HIV-associated head and neck

cancersP01 CA555121

H D F

Beckett, Sam

CD, CU 1 Quantum leap: Time travel as a novel HIV

prevention strategyR29 MH010101

C F C

Bullfrog, Jeremiah W. A.

CU1

Joy to the fishes in the deep blue sea: The development of a Zebrafish dendritic cell model in HIV

R37 CA010000

H H H

Croft, Lara CU 1 Archeological evidence of HIV in Egyptian tombs R23 AI555555

J J J

Omega, Zenith

CU, BDC 1 Aerosolized delivery of a cure for HIV R01

DA54321F,H,2 H C,D F,J H 2

* CD=Core Director, CU=Core User, BDC=Big Dogs Council

Rev 10/29/15 4

A.2PURPOSE: To document the support that CFAR Cores provided to projects NOT appearing on the most recent FRB.

Include a row for each NIH-funded project supported by the CFAR in the current reporting period, that does not appear in Appendix A.1o Do NOT include NIH-funded projects for which no CFAR Core assistance was provided

For each separate project list the Core(s) that provided a specific type of support for the project: consultation (C), equipment or space (E/S), materials (M), services (S), training (T) or other (O) – for that project.

Edit the standard “Roles” legend to include roles that are specific to your CFAR (see example below)

[The example table below is not comprehensive for the Urban CFAR’s Y10 reporting period]

Other NIH-funded Projects Supported by the CFAR

Name Roles*

Categories Grant Title Grant #CORES/SWGs THAT PROVIDED SUPPORT

C E/S M S T O

Badenov, Boris

CU, BDC 2 Using moose and squirrel to detect HIV in former

Soviet countriesD43 TW555121 H, C H F J

Baba, Ali2,5

Are opened sesames a magic bullet for AIDS-related cancer control?

NCI Admin Supplement B J J

Banzai, Buckeroo

CU, BDC 1

Innovative research housing for a griffin colony C06 0D018248 J 1

Calvin, Susan

CU, CD, SD

1Environmental obstacles to the use of sentient robots to provide HIV care in jungle and dessert settings

Core BB J B

Doolittle, John

CU3,5

Increasing Recruitment of Female Centaurs (“Fe-Mares”) in HIV Research

Core BB, C D C F B

Explorer, Dora

CU3,5

Where in the World is HIV? Core BB, H D H F B

Hackwrench, Gadget

CU4,5,6

New technologies for a rapid HIV test based on measuring aura color

NCCAM Admin Sup. B H F H

Jones, Indiana

BDC, CU 1

Arc of the covenant: Histo-religious distinctions in responses to HIV and AIDS

R36 MD200002 H F J

Mephisto, Alphonse

CU, SM 2,5

Nutritional Requirements of Vegan-Carnivore Chimera

Core BB, H F, J B

Neutron, Jimmy

BDC, CU 1

Adapting alien technology for use in cloning CD4+ effector memory T cells

R21 AI989898 J H H

* CD=Core Director, CU=Core User, SD=SWG Director, BDC=Big Dogs Council

Rev 10/29/15 5

Program Director/Principal Investigator (Last, First, Middle): Curran, James W.

Appendix B: Advisory Committee FindingsThe purpose of Appendix B is to describe the strategic planning recommendations that have been provided to your CFAR by committees established specifically for that purpose.

Appendix B.1Appendix B.1 should include the report from the most recent meeting of your External Advisory Board, if one has been held since the last progress report was submitted.

If no meeting of the External Advisory Board was held in the current reporting period say so here.

Do not include meeting agendas or materials provided to Advisory Board members

Appendix B.2The purpose of Appendix B.2 is to describe the recommendations and actions arising from any major meetings of your Internal Advisory Board (IAB) or other internal CFAR committees that were established specifically to provide scientific review and advice to the CFAR.

If no IAB meetings were held in the current reporting period say so here.

Do not include meeting agendas or materials provided to advisory committee members

PHS 398/2590 (Rev. 06/09) Page Continuation Format Page6

Appendix C.1 – All Core B ActivitiesPURPOSE: To provide the specifics for each funding application received by Core B in response to the mechanisms described in the “Application Summary Table” contained in the Core B narrative.

The example tables below are provided to illustrate the type of information you would provide for some of the mechanisms that were used in the examples provided in the Core B narrative Guidance. It is not expected that CFARs will provide these exact funding mechanisms.

The regulatory column is to ensure regulatory approvals (IRB, IACUC, HS/IRB Exemptions, and etc.) are current and up to date for supplement and pilot awards. Include the type of regulatory permission and the date of expiration for each. If a study has multiple institutions and/or sites, each applicable IRB expiration date must be listed.

If a study required clinical and/or international clearance, note yes and the type, or none required in the column “Clinical and/or Int’l Clearance Required”

Do not include paper copies of the regulatory documents. Regulatory permission types include, but not restricted to:

Domestic IRB Approvals International IRB Approvals IACUC Approval IBC Approvals HS/IRB Exemptions IRB Authorization Agreement Date

IRB approvals must be one year approvals or acknowledgement of a yearly review. IRB approvals must cover the duration of the study in which human subjects research was conducted.

ADMINISTRATIVE SUPPLEMENT APPLICATIONS AND AWARDSThe table below should list administrative supplements received since the last progress report was submitted. For each project listed below provide and abstract and progress report, as applicable, in Appendix C.2.1.ADMINISTRATIVE SUPPLEMENTS: NEWLY FUNDEDPD(s) Category Mentor Date

AwardedInstitute Title Clinical and/or

Int’l Clearance Required? (Y/N)

Regulatory Permission Type(s) and Expiration Date

Baba, Ail 2,5,6 Banzai Buckeroo

08/01/14 NCI Are open sesames a magic bullet for AIDS-related cancer control?”

Yes, Clinical Urban U. IRB Exp. 12/6/2016

The table below should list administrative supplement applications submitted to NIH that were not funded and describe what actions were subsequently taken. ADMINISTRATIVE SUPPLEMENT APPLICATIONS: NOT FUNDED

7

Applicant Category Applied Title OutcomeFalken, Stephen

3 11/1/14 The use of artificial intelligence in HIV prevention Research hypothesis is being rethought under mentor’s supervision (Alan Turing)

The table below should list administrative supplements that have already been reported in a previous progress report and are still active. For each project listed below provide a progress report in Appendix C.3.1. Also provide, in Appendix C.5, updated outcomes to date via the NIH’s Cumulative Outcomes Summary.ADMINISTRATIVE SUPPLEMENTS: ACTIVE PI(s) Category Date

AwardedInstitute Title Clinical and/or

Int’l Clearance Required? (Y/N)

Regulatory Permission Type(s) and Expiration Date

Shango, Bumba & Devi, Durga

4,5,64,5,6

10/01/13 NIAID South-South partnerships in AIDS vaccine research Yes, International and Clinical

Urban U. IRB Exp. 7/7/2016South African IRB Exp. 9/2/2016

The table below should list administrative supplements that finished their funded activities after the last progress report was submitted. For each project include a progress report in Appendix C.4.1. Also provide, in Appendix C.5, updated outcomes to date via the NIH’s Cumulative Outcomes Summary.

ADMINISTRATIVE SUPPLEMENTS: NEWLY COMPLETEDPI(s) Category Date

CompletedInstitute Title Clinical and/or

Int’l Clearance Required? (Y/N)

Regulatory Permission Type(s) and Expiration Date

Hackwrench, Gadget 4,5,6 07/15/14 NCCAM New technologies for a rapid HIV test based on

measuring aura colorNone required None required

INTERNAL FUNDING APPLICATIONS AND AWARDSThe table below should list internal awards given since the last progress report was submitted. For each project listed below provide and abstract and progress report, as applicable, in Appendix C.2.[#]. INTERNAL AWARDS: NEWLY FUNDEDPI(s) Category Mentor Date

AwardedMechanism Title Clinical and/or

Int’l Clearance Required? (Y/N)

Regulatory Permission Type(s) and Expiration Date

Doolittle, John 3,5 Buckeroo

Banzai 08/08/14 Microgrant Increasing Recruitment of Female Centaurs (“Fe-Mares”) in HIV Research

Yes, Clinical City U. IRB Pending, IACUC Exp. 6/17/2017

Moreau, N.F.N. 2,5

N/A (Category 2 applicant)

01/15/15 CFAR03 (Y10A)

Mouse/Macaque Models for AIDS Vaccine Studies

None required IACUC Exp. 5/27/2016

8

The table below should list applications received since the last progress report was submitted that were not funded and describe what actions were subsequently taken. INTERNAL APPLICATIONS: NOT FUNDEDApplicant Category Date Applied Mechanism Title OutcomeHound, Basset 2 11/1/14 Opportunity

AwardDevelopment of a Robust, Sensitive Microsphere-based Assay to Quantify FIV in Transgenic Cats Revising for resubmission

Farnsworth,Hubert J. (Mars U)

4 11/1/14 SWG 2 Seed Grant

Futurama: Cloning People as Old as Me who have the letters “H” “I” and “V” in their Name

No resubmission of this proposal will be accepted

The table below should list projects that have already been reported in a previous progress report and are still active. For each project listed below provide a progress report in Appendix C.3.[#].Also provide, in Appendix C.5, updated outcomes to date via the NIH’s Cumulative Outcomes Summary.INTERNAL AWARDS: ACTIVEPI(s) Category Mechanism Title Clinical and/or Int’l

Clearance Required? (Y/N)

Regulatory Permission Type(s) and Expiration Date

Explorer, Dora T 3,5 CFAR03

(Y09B) Where in the World is HIV?

Yes, International Urban U. IRB Exp. 2/23/2016, Zambia IRB Exp. 3/18/2016, Tanzania IRB Exp. 4/12/2016

The table below should list projects that finished their funded activities after the last progress report was submitted. For each project include a progress report in Appendix C.4.[#]. Also provide, in Appendix C.5, updated outcomes to date via the NIH’s Cumulative Outcomes Summary. INTERNAL AWARDS: NEWLY COMPLETEDPI(s) Category Date

CompletedMechanism Title Clinical and/or Int’l

Clearance Required? (Y/N)

Regulatory Permission Type(s) and Expiration Date

Mephisto, Alphonse 2,5

10/01/14 CFAR03 (Y08A)

Nutritional Requirements of Vegan-Carnivore Chimera

Yes, International Urban U. Exp: 1/18/2015, Malawi IRB Exp. 12/26/2015

OTHER CORE B ACTIVITIES

9

The purpose of this subsection is to summarize any other significant activities that Core B engaged in since the last report. The table or tables used to report the information may be formatted in any way that will help you summarize those Core B activities that provided the most value added. Do not attach flyers or RFA announcements

Conference SupportName Category ActivityBaba, Ali 2,5,6 Travel award; arranged for feedback on APHA conference oral presentation by members of SWG 2Croft, Laura: 1,5 Travel award; arranged for internal review of CROI abstract prior to (successful) submissionExplorer, Dora T: 3,5 Travel award: poster design tutorial and printing for presentation at APHA (Poster: “Where in the World is HIV?”)

Application SupportName Category ActivityCTSI N/A Review Committee for Core B helped review CTSI pilot project applications.Coyote, Wile E. 4,5 Solicited external reviews of draft R21 application.

Mentoring Activities

Mentee Mentor Frequency of Contact Activities Other Cores/SWGs Involved Outcome

Baba, Ali Angelika Pickes, Once a month Provided advice on assays

Virology Core Introduced to the Virology Core for development of new assay

Explorer, Dora T Christopher Columbus

Met weekly during application development, monthly since then

Introduced to research mentor and proposed foreign collaborators

Clinical and Immunology Cores

Supplement application submitted (funded),

Devi, Durga & Shango, Bumba

Indiana Jones Bi-monthly, via Skype Ongoing research mentoring for NIH administrative supplement award

Biostatistics and Virology Cores

South-South partnership established; All Urban University-based training complete; enrollment targets met

10

Appendix C.2 – New AwardsThe purpose of this appendix is to succinctly describe each newly-funded project reported in Appendix C.1. Follow the required format provided below.

Organization: Group reports by funding mechanism, with NIH supplements listed first (C.2.1). Provide a separate subsection (C.2.2; C.2.3 etc) for each internal mechanism. Within subsections, alpha order by contact PI’s last name.

Header: Follow the format provided in the examples below Not every project may have a mentor (e.g. senior faculty being brought into AIDS) Regulatory permission choices are: None, IRB, IACUC, NIH (Medical and/or International)

Abstract: Follow the same rules as for an NIH application abstract/project summary. Specifically: Limit length to 30 lines or less of text Include the project’s broad, long-term objectives and specific aims Include a description of the research design and methods for achieving the stated goals Do NOT include proprietary or confidential information, or trade secrets Write in plain language, so even a non-scientists can understand the importance of the project

Progress Report section: Limit length to amount of page remaining below completed header and abstract Include any information not being collected in the online NIH Cumulative Outcomes Summary – e.g.

oral and poster conference presentations

C.2.1: Newly Funded NIH Administrative SupplementsAli Baba, PhDAre Open Sesames a Magic Bullet for AIDS-related Cancer Control?Funded Activities Completed: N/AAward: $75,000Mechanism: NCI Administrative SupplementMentor(s): Buckeroo BonzaiProject Period: 08/01/14 – 07/31/15 Regulatory Permissions Required: IRB, NIH Medical Approval Date Report Received: 11/01/14

Abstract:[see instructions above]

Progress Report:This study is still in the preparation period.

NOTE: Although NIH medical approval is required do not attach copies of NIH medical checklist, protocol, emails between CFAR and NIH, or any other materials including targeted/planned enrollment tables.

11

C.2.2: Newly Funded CFAR03 Pilot ProjectsN.F.N. Moreau, MD, PhDMouse-Macaque Models for AIDS Vaccine StudiesFunded Activities Completed: N/AAward: $40,000Mechanism: standard CFAR03 (Y10A)Mentor(s): None (Category 2)Project Period: 01/15/15 – 01/14/16Regulatory Permissions Required: IACUCDate Report Received: 02/15/15

Abstract:[see instructions above]

Progress Report:This study is still in the preparation phase.

C.2.3: Newly Funded MicrograntsJohn Doolittle, MDIncreasing Recruitment of Female Centaurs (“Fe-Mares”) in HIV ResearchFunded Activities Completed: N/AAward: $2,000Mechanism: MicrograntMentor(s): Buckeroo BanzaiProject Period: 08/08/14 – 02/07/15 Regulatory Permissions Required: IRB, IACUCDate Report Received: 10/15/14

Abstract:[see instructions above]

Progress Report:This study is still in the preparation phase.

12

Appendix C.3 – Active AwardsThe purpose of Appendix C.3 is to provide a succinct update on progress made by active projects (including those operating under no cost extensions) since submission of the last progress report.

Do not provide progress reports for any project completely external to the CFAR. For example, projects funded by another organization for which Core B provided study section assistance may be described as a community outreach initiative in “Other Core B Activities” or “Other Key Achievements” but reports for those projects should not be included here.

Organization: As in Appendix C.2, group reports by funding mechanism, with NIH supplements listed first (C.3.1). Provide a separate subsection (C.3.2; C.3.3 etc) for each internal mechanism. Within subsections, alpha order by contact PI’s last name.

Header: Follow the format provided in the examples below Not every project may have a mentor (e.g. senior faculty being brought into AIDS) If project is operating under a No Cost Extension, use Project Period format as in Shango & Devi

example below Regulatory permission choices are: None, IRB, IACUC, NIH (Medical and/or International)

Progress Report section: Limit length to amount of page remaining below completed header (i.e., no report to exceed one page) Tables are permitted but do not include graphs, pictures, or articles in reports. Only include information that is new since the last progress report was submitted Include any information not being collected in the online NIH Cumulative Outcomes Summary – e.g.

information about oral and poster conference presentations

C.3.1: Active NIH Administrative SupplementsBumba Shango, PhD & Durga Devi MDSouth-South Partnerships in AIDS Vaccine Research (NIAID)Funded Activities Completed: N/AAward: $125,000Mechanism: NIAID Administrative SupplementMentor(s): Indiana JonesProject Period:

Original: 10/01/13 – 9/30/14NCE: 10/01/13 – 9/30/15

Regulatory Permissions Required: NIH International ClearanceDate Report Submitted: 9/15/14

Progress Report:This project has just received international clearance. We are awaiting receipt of a revised NGA from the NIH CFAR to begin funded activities.

C.3.2: Active CFAR03 Pilot ProjectsDora T. Explorer, PhDWhere in the World is HIV?Date Funded Activities Completed: N/AAward: $40,000Mechanism: Co-funded CFAR03 (Urban University Dept. of Global Health)Mentor(s): Christopher Columbus

13

Project Period: 08/15/14 – 08/14/15 Regulatory Permissions Required: NIH International ClearanceDate report received: 8/15/14

Progress Report:[Insert here]

Appendix C.4 – Newly Completed ProjectsThe purpose of Appendix C.4 is to provide a summary report for projects that have completed funded activities since submission of the last progress report.

Do not provide reports for any project completely external to the CFAR. For example, projects funded by another organization for which Core B provided a poster design tutorial may be described in “Other Core B Activities” but should not be included here.

Organization: As in Appendix C.2, group reports by funding mechanism, with NIH supplements listed first (C.4.1). Provide a separate subsection (C.4.2; C.4.3 etc) for each internal mechanism. Within subsections, alpha order by contact PI’s last name.

Header: Follow the format provided in the examples below Not every project may have a mentor (e.g. senior faculty being brought into AIDS) If project included a No Cost Extension, use Project Period format as in Mephisto example below Regulatory permission choices are: None, IRB, IACUC, NIH (Medical and/or International)

Summary Report section: Limit length to amount of page remaining below completed header (i.e., no report to exceed one page) Tables are permitted but do not include graphs, pictures, or articles in reports. Briefly summarize project activities and outcomes Include any information not being collected in the online NIH Cumulative Outcomes Summary – e.g.

information about oral and poster conference presentations

Future Plans section Limit length of “Future Plans” section plus “Value Added” section plus “Regulatory Permissions” header

and descriptive text to one page total Describe the PI’s next steps for use of the findings and how this project will lead to future NIH funding

Value Added by the CFAR section See comment about Value Added section length in “Future Plans” instructions above Describe why the PI is happy to have received the money – i.e. what she or he was able to accomplish

that they wouldn't have been able to had it not been for the award. For example, "Because of the Developmental Core award Dr. X …. " or "If it hadn't been for the Developmental Core award Dr. X would not have been able to …."

C.4.1: Newly Completed NIH Administrative SupplementsGadget Hackwrench, PhDNew technologies for a rapid HIV test based on measuring aura color Funded Activities Completed: 07/15/14Award: $50,000Mechanism: NCCAM Administrative SupplementMentor(s): Zenith OmegaProject Period: 08/01/13 – 07/31/14Regulatory Permissions Required: NoneDate report received: 09/01/13

14

Summary Report:[insert report here]

Future Plans:[insert report here]

Value Added by the CFAR:[insert report here]

C.4.2: Newly Completed CFAR03 Pilot ProjectsAlphonse Mephisto, MD, PhDMouse/Macaque Chimeras: The Next Generation Model Funded Activities Completed: 10/01/14Award: $40,000Mechanism: Standard CFAR03 Mentor(s): None (Category 2)Project Period:

Original: 11/01/12 – 10/31/13NCE: 11/01/12 – 10/31/14

Regulatory Permissions Required: IACUC Date report received: 11/15/14

Summary Report:[insert report here]

Future Plans:[insert report here]

Value Added by the CFAR:[insert report here]

15

NOTECore B Awards Outcome Summary, 2000 – current

Please keep updated Core B Awards Outcomes Summary documents in excel format. Program will request these towards the end of the fiscal year.

16

Appendix D – CFAR Science Core ActivitiesThe purpose of this appendix is to describe the support provided for CFAR- and NIH-funded projects and other key activities of the Core.

Report information for each Science Core in a separate Appendix (D.1, D.2, D.3, etc). Divide information into two tables: 1) Support for NIH-Funded Projects; 2) Other Significant Activities. The “% Use” column for the two tables should cumulatively equal 100% List Core B projects first, followed by NIH Admin Supplements, followed by NIH awards Put the names of first time core users in italicized font; put NIH grant numbers appearing on FRB in bold face font Under “Core Services Provided” Label the Value Added Activity by type and then provide enough detail to make it clear how the user

benefitted from their interaction with the Core (see Core Support legend beneath example Table #1 below)

Appendix D.[X] – Core HCore H Utilization Table: Support for Core B- and NIH-Funded ProjectsInvestigator (location)Collaborator (location) Category “Core B” or NIH

Grant NumberTitle of Project Core Services Provided % Use

Calvin, Susan (Urban U) &Boop, Betty (Suburban CFAR)

1Core B Environmental obstacles to the use of

sentient robots to provide HIV care in jungle and dessert settings

Space: Provided use of BSL2 facility 3

Explorer, Dora T. (Urban Univ) 3,5 Core B Where in the World is HIV? Consulting: Advice on study design

Services: cell sorting 3

Mephisto, Alphonse (Urban Univ) 2,5 Core B Nutritional Requirements of

Vegan-Carnivore ChimeraConsulting: Advice on study design <1

Hackwrench, Gadget (Urban Univ) 4,5,6 NIH Admin Supp New technologies for a rapid HIV test

based on measuring aura colorTraining: Use of flow cytometerEquipment: Access to flow cytometer

4

Badenov, Boris (Urban Univ) 2 D43 TW555121 Using moose and squirrel to detect

HIV in former Soviet Block countriesMaterials: Provided assays and specimens

12

Banzai, Buckeroo (Urban Univ.) 1 P01 CA555121 Giraffe models of HIV-associated

head and neck cancersConsulting: Advice on study design 10

Beckett, Sam (Urban Univ) 1 R29 MH010101 Quantum leap: Time travel as a novel

HIV prevention strategyTraining: Use of flow cytometer <1

Bullfrog, Jeremiah W.A. (Urban Univ) 1

R37 CA010000 Joy to the fishes in the deep blue sea: The development of a Zebrafish

dendritic cell model in HIV

Services: Dendritic cell sorting 13

Jones, Indiana (Urban Univ) 1

R36 MD200002 Arc of the covenant: Histo-religious distinctions in responses to HIV and

AIDS

Consulting: Advice on study design <1

Neutron, Jimmy (Rural CFAR) 1 R21 AI989898 Adapting alien technology for use in

cloning CD4+ effector memory T cellsTraining: BSL2 protocolsServices: Provided tetramer staining

10

Omega, Zenith (Urban Univ) 1 R01 DA54321 Aerosolized delivery of a cure for HIV Space: Access to a BSL3 facility

Services: Use of BSL3 staff9

17

Core H: Other Significant ActivitiesType Activity % UseTraining Provided training for 10 labs on flow cytometer use and training for 5 labs on BSL3 protocols 15Services Developed 18 novel assays to increase capacity of the Core 20

Other Performed flow assays for CDC-funded project (Disease Surveillance in Parallel Universes; Dr. Who, PI) that enabled first ever research collaboration between Urban University CFAR scientists and CDC scientists <1

The purpose of the table above is to describe other activities that EITHER took significant amounts of Core time OR provided significant value added. Format table as needed to present the information as succinctly and quantitatively as possible.

The “% Use” column for Tables 1 and 2 should cumulatively equal 100%.

18